RETINOSTAT

USPTO USPTO 2003 CANCELLED - SECTION 8

Schützen Sie diese Marke vor Nachahmern!

Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.

Die US-Marke RETINOSTAT wurde als Wortmarke am 11.06.2003 beim Amerikanischen Patent- und Markenamt angemeldet.
Sie wurde am 22.01.2008 im Markenregister eingetragen. Der aktuelle Status der Marke ist "CANCELLED - SECTION 8".

Markendetails

Markenform Wortmarke
Aktenzeichen 78260879
Registernummer 3372819
Anmeldedatum 11. Juni 2003
Veröffentlichungsdatum 10. April 2007
Eintragungsdatum 22. Januar 2008

Markeninhaber

The Oxford Science Park
OX4 4GA Oxford
GB

Markenvertreter

Waren und Dienstleistungen

1 Chemical and biochemical products for use in gene delivery technology, namely, enzymes; chemical products for in-vitro use in laboratories and for analysis in gene delivery technology, micro-organisms, cell cultures, plasmids and cultures of micro-organisms, deoxyribonucleic acid sequences, cloning vehicles and recombinant deoxyribonucleic acid variations thereof, all for in-vivo use in gene delivery technology
5 Gene therapy and prophylaxis products, namely, gene delivery, gene transfer, gene regulation and gene modulation for the treatment of [ blood disorders, cancers, diseases of the nervous system, ] macular degeneration, diabetic retinopathy, [ diabetes, inflammatory and auto-immune diseases, vascular disorders, ] disorders arising from improper vascularisation and single gene disorders; pharmaceutical substances and preparations for use in the medical industry, namely, vaccines, enzymes and enzyme preparations, anti-apoptopic and angiostatic/angiogenic molecules, retroviral vector and retroviral vector manufacturing preparations, all for use in gene delivery technologies, vector production technologies and neurogenomics products; chemical products for use in medical science, particularly for treatment of disease of the eye, vascular and neovascularisation disorders and retinopathy; pharmaceutical and biochemical preparations for the treatment of macular degeneration and retinopathy [ and angiogenesis; ] instruments and apparatus for the administration of gene and [ antibody-based ] therapy and prophylaxis preparations and substances, namely, pre-filled vials, syringes and injectors for medical purposes
42 Scientific and medical research and development; [ engineering services, biotechnology services, namely, biotechnology research in the development of therapeutic and prophylactic products and vaccines; licensing of intellectual property; ] advisory services relating to the research and development of gene therapy; consultation services in the fields of medical and scientific research in the field of professional gene therapy [; medical research and development in the field of vector production technologies ]
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen

ID: 1378260879